Copy
Email not displaying correctly? View it in your browser   

AntoXa Corporation granted DRDC license for novel, plant-made anti-ricin antibody

PlantForm subsidiary AntoXa Corporation has obtained a license from Defence Research & Development Canada (DRDC), an Agency of the Canadian Department of National Defence, to develop and produce an anti-ricin monoclonal antibody for sale in markets worldwide.

The licensing agreement follows work conducted with DRDC to develop and produce the plant-made antibody PhD9 as a medical countermeasure for ricin exposure, a program that has received more than $600,000 (CAD) from the Government of Canada since 2014.

“We anticipate market entry for the PhD9 anti-ricin antibody within two to three years, a timeline that is dependent on raising the necessary funds for scale up and other activities necessary to obtain regulatory approvals,” said Ashley Meyers, AntoXa Chief Technical Officer.

“This antibody will be produced in the vivoXPRESS® plant-based manufacturing system licensed from PlantForm Corporation, which uniquely addresses the critical need for cost-effective, large-scale production of antidotes for ricin and other potential terrorism threats.”

See the press release.
Subscribe to AntoXa news.
Follow AntoXa on Twitter and LinkedIn.
 

Share our newsletter:
   

Keep in touch:
Get regular updates on our activities and industry news by following PlantForm on Twitter, LinkedIn and Facebook:
 
Facebook page - PlantForm
April 2018

Events

PlantForm CEO Don Stewart will be at the CPhI North America 2018 conference in Philadelphia 24-26 April, 2018. Email Don to arrange a meeting. #CPhINorthAmerica

 
Management Team

Don Stewart, PhD
President & CEO

David Cayea, BA
Chief Operating Officer

Ron Hosking, CA
Chief Financial Officer

J. Christopher Hall, PhD
Chief Scientific Officer

Doug Cossar, PhD
Vice-President, Research

Craig Binnie, PhD
Vice-President, Drug Development


Board of Directors

Warren Whitehead, MBA
Chairman of the Board of Directors
Former CFO, Arius Research

Mark Goldberg, PhD, DABT, C.Dir.
Founder and former CEO, GlobalTox

James Rae
CEO, Viron Therapeutics Inc.

J. Christopher Hall, PhD
CSO, PlantForm Corp.

Don Stewart, PhD
President & CEO, PlantForm Corp.


 
PlantForm Corporation is a biopharmaceutical company focused on the rapid development and production of specialty antibody and protein drugs using the plant-based vivoXPRESS® manufacturing platform.
 
Our mailing address is:
1920 Yonge St, Suite 200
Toronto, Ontario
M4S 3E2  CANADA
For more information, contact:
Don Stewart
President & CEO
416-452-7242
 
Email Marketing Powered by Mailchimp






This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
PlantForm Corporation · 1920 Yonge Street, Suite 200 · Toronto, Ontario M4S 3E2 · Canada

Email Marketing Powered by Mailchimp